MedX Health Appoints SIAscopy Co-Developer Dr. Symon D. Cotton to Advance AI Teledermatology and Early Skin Cancer Detection

MedX Adds Dr. Symon D. Cotton as Strategic Advisor: Practical Takeaways for Product Teams

MedX Health Corp. appointed Dr. Symon D. Cotton-co-developer of SIAscopy-as Strategic Advisor. This move ties deep optics expertise to MedX's teledermatology platform, DermSecure, and its imaging dataset.

For product leaders, this is a signal: pair proprietary data with domain-specific AI, and ship devices and software that meet clinical and commercial measures at scale.

Why this matters

SIAscopy enabled non-invasive, simultaneous measurement of melanin, hemoglobin, and collagen-data layers that help clinicians see beyond the surface. That signal density is rare, and it trains better models when paired with rigorous labels and outcomes.

MedX already operates across multiple regulated markets. Combining a distinctive imaging method with AI and a secure telederm workflow is a defensible stack: sensor + data + model + workflow + clearance.

What product teams can learn

• Data advantage is practical, not abstract: Rich, structured signals (melanin/hemoglobin/collagen) enable features clinicians value-higher diagnostic confidence, fewer unnecessary referrals, and faster triage.
• Model performance must map to care pathways: Optimize for sensitivity where early cancer detection matters; use specificity and PPV to manage downstream workload.
• Human-in-the-loop is non-negotiable: Dermatologist review via a secure workflow (DermSecure) turns AI from suggestion to supervised decision support.
• Device + software co-design: Imaging fidelity, consistency, and calibration upstream reduce label noise and model drift downstream.
• Regulatory leverage: Clearances across regions shorten sales cycles and create distribution options; keep documentation and post-market surveillance audit-ready.
• Commercial scalability: Prioritize integrations (EHR, PACS), deployment speed, and training time to value for clinicians and clinic staff.

Execution checklist for your roadmap

• Define clinical KPIs per market: sensitivity/specificity thresholds, time-to-report, referral rate impact, and dermatologist acceptance rate.
• Stand up a strict data pipeline: imaging SOPs, calibration protocols, and outcomes-linked labels; monitor for drift across devices and sites.
• Build tiered triage: high-risk fast-lane, routine queue, and auto-education for low-risk follow-ups with clinician oversight.
• Evidence plan: prospective studies with external validation; report AUC, sensitivity at fixed specificity, confidence intervals, and subgroup analysis.
• Integrations: FHIR-based results, SSO, role-based access, and encrypted storage with clear data residency policies.
• Go-to-market focus: target clinics with screening backlogs; quantify ROI via reduced unnecessary biopsies and shorter wait times.

Voices from the announcement

"I am proud to have been part of the original SIAscopy journey and excited to rejoin the field with MedX at such a pivotal moment," said Dr. Symon D. Cotton. "With AI poised to transform teledermatology, I look forward to helping MedX leverage its unmatched imaging database and DermSecure platform to improve early skin cancer detection worldwide."

John Gevisser, CEO of MedX Health, said: "Dr. Cotton's contribution to SIAscopy was instrumental in shaping the technology that supports MedX's global teledermatology platform today. His expertise in medical device innovation and computational and AI strategy will help us extend our leadership at the forefront of skin optics and machine learning, ensuring MedX solutions remain both clinically rigorous and commercially scalable."

About MedX Health Corp.

MedX Health Corp., based in Ontario, Canada, provides non-invasive skin assessment and teledermatology solutions. Its SIAscopy technology, integrated into the DermSecure platform, captures accurate lesion images for dermatologist review.

MedX reports that its products are cleared for use in 38 territories, including Canada, the U.S., Australia, New Zealand, the U.K., the EU, and Turkey. For regulatory context, see device frameworks from the U.S. FDA and Health Canada.

Practical next step for product leaders

If you're building AI-enabled clinical products, upskill your team on model evaluation, regulatory expectations, and workflow design. Explore role-specific learning tracks here: AI courses by job.

Notes

This announcement may include forward-looking statements that involve risks and uncertainties. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of the release.

Media contact

MedX Health Corp.
John Gevisser, CEO - MedX Health Corp.
john.gevisser@medxhealth.com
(+1) 905-670-4428